You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Balancing HDL-C Levels: How Much Is Too Much?

  • Authors: News Author: Marilynn Larkin; CME Author: Charles P. Vega
  • CME / ABIM MOC / CE Released: 3/3/2023
  • Valid for credit through: 3/3/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, endocrinologists, cardiologists, nurses, pharmacists, physician assistants, and other members of the healthcare team who care for older adults.

The goal of this activity is for learners to be better able to assess the relationship between high-density lipoprotein cholesterol (HDL-C) and the risk for fracture among older adults.

Upon completion of this activity, participants will:

  • Evaluate the risk for mortality based on HDL-C among adults with coronary artery disease
  • Assess the relationship between HDL-C and the risk for fracture among older adults
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Marilynn Larkin

    Freelance writer, Medscape

    Disclosures

    Marilynn Larkin has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor/Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-089-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 03/03/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Balancing HDL-C Levels: How Much Is Too Much?

Authors: News Author: Marilynn Larkin; CME Author: Charles P. VegaFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/3/2023

Valid for credit through: 3/3/2024, 11:59 PM EST

processing....

Clinical Context

High-density lipoprotein cholesterol (HDL-C) has traditionally been known as the "good" cholesterol, as older studies have found that elevated levels of HDL-C are associated with lower rates of cardiovascular (CV) events; however, medications such as niacin, estrogen, and cholesterol ester transfer protein inhibitors, which raise HDL-C, have not been associated with better CV outcomes, and more recent studies have suggested a positive relationship between HDL-C and CV risk.

Liu and colleagues performed one such study, and their results were published in the May 18, 2022 issue of JAMA Cardiology.[1] They used 2 large databases of health information on adults, the UK Biobank and Emory Cardiovascular Biobank, to find adults with known coronary artery disease (CAD) and compare outcomes of these individuals based on HDL-C levels ≤ 80 mg/dL or > 80 mg/dL.

Overall, there was a U-shaped relationship between HDL-C and the risk for death in adjusted analyses, with a near 2-fold increase in mortality among adults with HDL-C > 80 mg mg/dL compared with the control group. Very high HDL-C was also associated with a significant 71% increase in the risk for CV death specifically. Men with very high HDL-C seemed particularly at higher risk for mortality compared with women.

Perhaps even more surprising, some research has linked high HDL-C with higher risks for osteoporosis and fracture. The current study by Hussain and colleagues explores this subject further.

Study Synopsis and Perspective

High levels of HDL-C in older adults are associated with a higher risk of sustaining a fracture than in older adults with lower HDL-C levels, a new study suggests.

"Two animal studies showing that HDL-C reduces bone mineral density by reducing osteoblast number and function provide a plausible explanation for why high HDL-C may increase the risk of fractures," Monira Hussain, MBBS, MPH, PhD, of Monash University in Melbourne, Australia, told theheart.org | Medscape Cardiology. "So, it was not surprising when our analyses provided evidence that amongst those in the highest quintile of HDL-C (> 74 mg/dL) there was a [33%] increased risk of fractures."

After adjustment, one standard deviation increment in HDL-C level was associated with a 14% higher risk for fracture during a 4-year follow-up.

Based on this and other studies, Hussain said, "I believe that the finding of a very high HDL-C [should] alert clinicians to a higher risk of mortality, fractures, and possibly other threats to their patient's health."

The study was published online January 18 in JAMA Cardiology.[2]

Independent Risk Factor

For this report, the researchers conducted a post-hoc analysis of data from the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial[3] and the ASPREE-Fracture substudy.[4]

ASPREE was a double-blind, randomized, placebo-controlled primary prevention trial of aspirin. Participants were 16,703 community-dwelling Australians and 2411 individuals from the United States with a mean age of 75 ± 4 years without evident cardiovascular disease (CVD), dementia, physical disability, or life-limiting chronic illness.

The ASPREE-Fracture substudy collected data on fractures reported postrandomization from the Australian participants. Fractures were confirmed by imaging and adjudicated by an expert panel and included both traumatic and minimal trauma fractures.

Of the 16,262 participants who had a plasma HDL-C measurement at baseline (55% women), 1659 (10.2%) experienced at least 1 fracture over a median of 4 years. This included 711 minimal trauma fractures (eg, falls from standing height) and 948 other trauma fractures, mainly falls on stairs, ladders, or stools.

Higher rates of fractures occurred in the highest quintile of HDL-C level where the mean level was 89 mg/dL. At baseline, participants in that quintile had a lower body mass index (BMI), a high prevalence of current/former smoking and current alcohol use, 12 years or longer of school, more physical activity, and higher use of antiosteoporosis medication. They also had less chronic kidney disease, diabetes, prefrailty/frailty, or treatment with lipid-lowering drugs.

In a fully adjusted model, each standard deviation increment in HDL-C level was associated with a 14% higher risk for fractures (HR 1.14). When analyzed in quintiles (Q), compared with participants in Q1, persons in Q5 had a 33% higher risk for fracture (HR 1.33).

Prevalence rates were similar between the sexes. The increase in fracture risk appeared to be independent of traditional risk factors for fractures, including age, sex, physical activity, alcohol use, frailty, BMI, smoking status, diabetes, chronic kidney disease, use of lipid-lowering or anti-osteoporosis drugs, and education, the authors noted.

The results persisted in sensitivity analyses in restricted subgroups of interest and in stratified analyses, including, for example, only minimal fractures; participants not taking anti-osteoporosis drugs or statins; never smokers; nondrinkers; and participants engaging in minimal physical activity (walking < 30 min/d).

No association was observed between non--HDL-C levels and fractures.

The authors concluded that the study, "provides robust evidence that higher levels of HDL-C are associated with incident fractures in both male and female individuals, independent of conventional risk factors."

Clinically Useful?

Commenting on the study fortheheart.org | Medscape Cardiology, Marilyn Tan, MD, clinic chief of the Endocrine Clinic and clinical associate professor of medicine at Stanford University School of Medicine, Stanford, California, said, "I certainly would not recommend anyone do anything to actively lower their HDL levels. HDL levels are largely determined by genetics, diet, and lifestyle, with some effects from certain medications/supplements. Studies have demonstrated that moderately higher HDL levels may be protective for atherosclerosis."

In the current study, she said, "Causation has not been proven, and importantly there is no evidence that reducing HDL levels reduces fracture risk. Also, this association between raised HDL levels and fracture risk has not been demonstrated consistently in other studies."

Furthermore, she noted, the preclinical trials on which the authors based their hypothesis (ie, an association between HDL-C and a reduction in the number and function of osteoblasts) "has not been demonstrated widely in human subjects."

"We have a large armamentarium of FDA-approved treatments for osteoporosis that have been clinically proven to reduce facture risk very significantly, and these are the tools [in addition to lifestyle changes] we should use to reduce fracture risk," Tan concluded.

John Wilkins, MD, of Northwestern University Feinberg School of Medicine in Chicago, Illinois, and Anand Rohatgi, MD, MSCS, of The University of Texas Southwestern Medical Center in Dallas, Texas, also pointed out some limitations of the study in a related editorial.[5]

They noted the inclusion of predominantly healthy adults with a mean age of 75 ± 4 years, a population that could yield different findings from middle-aged cohorts with chronic illnesses, as well as a lack of clarity regarding the possible role of alcohol intake among the study participants.

Furthermore, the editorialists wrote, although significant associations were shown in this study, "models were not adjusted for detailed measures of exercise/activity, triglycerides, or any other lipids, including other HDL compositional measures such as [high-density lipoprotein particle number (HDL-P)] or [apolipoprotein AI (ApoA-I)] levels. There was no assessment of whether HDL-C improved discrimination, reclassification, or any other validated measures of risk prediction performance.

"Taken together," they concluded, "this study alone leaves several unanswered questions as to whether high HDL-C could be a useful biomarker to detect fracture risk."

No commercial funding was disclosed. The authors reported no relevant financial relationships.

Study Highlights

  • Researchers drew study data from the Aspirin in Reducing Events in the Elderly study, a randomized trial of aspirin vs placebo among older adults in Australia and the United States. All participants were free of CVD and dementia at baseline.
  • Participants underwent a complete laboratory assessment, including fasting lipid profiles, and physical examination at baseline. Researchers followed them for major clinical events prospectively, including fracture.
  • The current study assessed the relationship between HDL-C levels and the incidence of fracture. The study analysis was adjusted to account for demographic, health habit, and chronic disease variables, as well as BMI and the use of medications, such as statins and anti-osteoporosis drugs.
  • 16,262 adults were included in the current analysis. 55% of participants were female, and the mean age was 75 ± 4 years. 38% had some positive measure of frailty.
  • The overall rate of fracture was 10.2% over 4 years of follow-up. There were 711 fractures associated with minimal trauma and 948 fractures due to more significant trauma. More significant trauma included falls down stairs or from ladders.
  • High HDL-C levels were associated with lower BMI, higher rates of smoking and alcohol use, greater physical activity, higher educational attainment, and greater use of anti-osteoporosis medications.
  • There was a fairly linear positive relationship between HDL-C levels and the risk for fracture among both women and men. Each 1-standard deviation increase in HDL-C was associated with an HR of 1.14 (95% CI: 1.08, 1.2) for fracture.
  • Compared with the quintile with the lowest HDL-C levels, participants in the highest quintile experienced an HR of 1.33 (95% CI: 1.14, 1.54).
  • No other lipid particles were significantly associated with the risk for fracture.
  • Subgroup analyses based on fracture type, statin and anti-osteoporosis drug use, and physical activity level failed to alter the main study conclusions.

Clinical Implications

  • A previous study by Liu and colleagues of adults with CAD found a U-shaped relationship between HDL-C and the risk for death in adjusted analyses, with a near 2-fold increase in mortality among adults with HDL-C > 80 mg mg/dL compared with the control group. Very high HDL-C was also associated with a significant 71% increase in the risk for CV death specifically. Men with very high HDL-C seemed particularly at higher risk for mortality compared with women.
  • The current study by Hussain and colleagues demonstrates a linear positive relationship between HDL-C levels and the risk for fracture among older women and men. Subgroup analyses based on fracture type, statin and anti-osteoporosis drug use, and physical activity level failed to alter the main study conclusions.
  • Implications for the healthcare team: The healthcare team should not assume that high levels of HDL-C are salutary for older adults.

 

Earn Credit

  • Print